The Food and Drug Administration has decided to allow pharmacists to continue producing compounded versions of tirzepatide, the active ingredient in Eli Lilly’s diabetes and weight loss drugs, while it reevaluates its decision to remove the drug from the nationwide shortage list. This decision follows a lawsuit by the Outsourcing Facilities Association claiming that the drug is still in short supply and should remain on the shortage list. Patients and compounding pharmacists are relieved by this decision, as they rely on compounded versions of the drug for accessibility and affordability.
Tirzepatide was initially approved to treat Type 2 diabetes, but off-label usage for weight loss led to increased demand, exacerbating shortages. Despite Lilly’s claims that the drug is not in shortage, reports from patients and caregivers suggest otherwise. Compounding pharmacists emphasize the importance of access to these medications for patients who rely on them for their health.
Although the FDA’s decision is seen as a victory by many, there is still skepticism in the patient community about the agency’s future actions. Patients like Simone Williams and Elizabeth Kenly, who rely on compounded tirzepatide, are relieved by the decision, but remain cautious about potential changes in the future. The compounding industry argues that the supply chain for GLP-1 medications is not stable, highlighting the financial stakes involved in these decisions.
While the FDA’s decision offers some peace of mind to patients and pharmacists, there is ongoing uncertainty about the availability of tirzepatide and the legality of compounding practices. The industry groups are pushing for clarity from the FDA to ensure that patients can continue to access the medications they need.
Photo credit
www.nbcnews.com